Sexton Biotechnologies


  1. Torres Chavez, A. et al. Choice of serum for ex vivo expansion determines in vivo CAR T cell function.
  2. Torres Chavez, A. et al. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer 7, (2019).
  3. Riis, S., Nielsen, F. M., Pennisi, C. P., Zachar, V. & Fink, T. Comparative Analysis of Media and Supplements on Initiation and Expansion of Adipose-Derived Stem Cells. Stem Cells Transl Med 5, 314–324 (2016).
  4. MSC White Paper Optimizing Production.
  5. Covid-19 – Safety and Supply of Ancillary Materials (22Apr2020).
  6. MSC White Paper Optimizing Production (May 2020).
  7. Copland, I. B., Garcia, M. A., Waller, E. K., Roback, J. D. & Galipeau, J. The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. Biomaterials 34, 7840–7850 (2013).
  8. Canestrari, E., Steidinger, H. R., Charlebois, S. J. & Dann, C. T. Human platelet lysate media supplement supports lentiviral transduction and expansion of human T lymphocytes while maintaining memory phenotype Running title (50 characters): Human platelet lysate for producing modified T cells.
  9. Cooper, R. S. et al. Rapid GMP-Compliant Expansion of SARS-CoV-2–Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19. Front Immunol 11, (2021).
  10. Dann – A new PL alternative to serum for ex vivo transduction and expansion of human T cells (ASGCT 2018).
  11. Thompson, S. et al. Improving the quality cell yield of T-cell immunotherapies through selective pressures imparted by culture media supplements. Cell Gene Ther Insights 6, 287–294 (2020).
  12. Haack-Sørensen, M. et al. Development of large-scale manufacturing of adipose-derived stromal cells for clinical applications using bioreactors and human platelet lysate. Scand J Clin Lab Invest 78, 293–300 (2018).
  13. Haack-Sørensen, M., Johansen, E. M., Højgaard, L. D., Kastrup, J. & Ekblond, A. GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use. Stem Cells Int 2022, (2022).
  14. Charlebois – Characterization of a Pathogen-Reduced hPL (ISCT 2018).
Scroll to Top